The Nephrotoxicity of Checkpoint Inhibitors: A Mini Review

Fariba Mahmoodpoor1, Mohammadreza Ardalan2, Aygun Nasibova3, Mahbuba Valiyeva4, Elham Ahmadian1,2

1Research Center for Integrative Medicine in Aging, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
2Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3Department of Biophysics and Biochemistry, Baku State University, Baku, Azerbaijan
4Department of Pharmaceutical Technology and Management, Azerbaijan Medical University, Baku 1022, Azerbaijan

Article History:
Received: July 10, 2023
Accepted: December 11, 2023
ePublished: February 21, 2024

*Corresponding Author:
Elham Ahmadian,
Email: ahmadian.elham@yahoo.com


Abstract

Immune checkpoint inhibitors (ICIs) have established promising therapeutic outcomes in the treatment of more than 17 tumors and are being used more frequently. Although these drugs have made progress in cancer treatment over the past ten years, severe immune-related adverse events (irAEs) can be fatal. Nephrotoxicity is less frequent than toxicities that affect the gastrointestinal tract, the skin, and the endocrine system, yet it is frequently underdiagnosed because of its difficulty. The most frequent nephrotoxicity is acute kidney injury (AKI), which is typically linked to acute interstitial nephritis. It is possible for kidney impairment caused by ICIs to manifest in much more varied ways, which may have an impact on the management strategies for therapeutic as well as diagnostic purposes. The current study discussed the most recent ICIs for cancer that have been approved, the risk factors and prevalence of nephrotoxicity, the present knowledge of the pathological mechanisms of AKI, and the management protocols.

Keywords: Nephrotoxicity, Acute kidney injury, Cancer, Checkpoint inhibitor

Introduction

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies developed to control the negative feedback loop of the immune system by blocking the surface receptors that are primarily found on immune cells such as B and T cells and some tumor cells.1-3 ICIs can prohibit or/and take away the brakes from the immune system by attaching to these receptors. As a result, ICIs increase T cell activation and have antitumor effects.4 The CD28 homolog CTLA-4 or CD152 is a protein mostly expressed in T cells and is allied with cytotoxic T cells (Figure 1).

B7 (CD80/86) is mostly found on antigen-presenting cells, and CTLA-4 has a high affinity for it. This affinity can reduce and/or impede the activation of T cells.5 The U.S. Food and Drug Administration (FDA) approved the initial ICI mediation, ipilimumab, a CTLA-4 inhibitor, for the treatment of melanomas in 2011.6 Six ICIs, including protein 1 (PD-1) (cemiplimab, pembrolizumab, nivolumab), or PD-ligand 1 (PD-L1) (atezolizumab, durvalumab, and avelumab), that target programmed cell death have been approved by the FDA after ipilimumab was approved.7 The incidence of anti-PD-1-mediated nephrotoxicity is significantly higher in all grades compared to control groups.8

Only one-third of patients receive benefits from immunotherapy, which has replaced chemotherapy as the treatment of choice for some cancers, while the other two-thirds endure unfavorable, and occasionally fatal, side effects.9 These negative consequences, also known as immune-related adverse events (irAEs), are brought on by autoimmune conditions that can possibly affect all tissues and range in severity. The most frequent and manageable irAEs are cutaneous, gastrointestinal, and endocrine dysfunctions. Other organs such as kidneys are generally less affected but are more challenging to diagnose and treat.10 The adverse effects are related to the type of ICIs, and the severity and frequency with anti-CTLA4 antibodies (particularly ipilimumab) are higher.11

A small percentage of patients have acute kidney injury (AKI), which typically results from acute interstitial nephritis related to ICIs (ICI-AKI).12 AKI concomitant with proteinuria may be observed. The most common lesion observed on kidney biopsy is tubulointerstitial nephritis and glomerular lesions, while acute tubular injury occurrence is less common. Kidney biopsy is necessary in the majority of patients for the definitive diagnosis and therapeutic guide of the renal lesion.13,14

Electrolytic disorders and imbalances such as hypokalemia, hypocalcaemia, hypernatremia, and Fanconi syndrome necessitate close observation to prevent potentially fatal side effects. Steroid administration and/or
ICI interruption are the pipelines of renal irAEs treatment since they help avoid irrecoverable organ damage. The management of ICI nephrotoxicity is important for the quality of life in cancer cases and their survival. The present review represented the most recent data on ICI-AKI incidence, risk factors, and treatment options while assessing potential management scenarios.

Nephrotoxicity Related to Immune Checkpoint Inhibitors

The frequency of nephrotoxicity with ICI treatment has been studied in a few systematic reviews and meta-analyses. In cancer therapy, the severity rating system for adverse events identified as the Common Terminology Criteria for Adverse Events (CTCAE) is widely acknowledged. Depending on the rise of serum creatinine (sCr) above the reference range, this system determines five classes of AKI. However, frequently decreased muscle mass is observed in cancer cases, which can affect how any surge in creatinine is perceived. The work group of the Kidney Disease Improving Global Outcomes (KDIGO) consensus, on the other hand, categorizes AKI into three stages based on sCr changes.

The incidence of AKI was 2.2% overall and 0.6% for grade 3 AKI in a pooled study of 3695 patients who received ICIs in phase II and III clinical trials. According to a meta-analysis of 4070 patients, those using ICIs had a higher likelihood of developing all-grade nephrotoxicity than patients receiving chemotherapy, but in high-grade AKI, there was no difference within the groups. In addition, it has been shown that the combined risk of ipilimumab and nivolumab is greater than the risk of ipilimumab or nivolumab alone. In another meta-analysis of 5722 patients, the data were obtained from ten clinical trials in which 9 studies used ICIs as monotherapy, and in one study patients received both ipilimumab and nivolumab. While the prevalence of high-grade renal toxicity was comparable, the incidence of anti-PD-1-mediated kidney adverse effects of all grades was considerably higher compared to controls. Furthermore, previous chemotherapy regimens had no impact on the incidence of ICI-AKI, while pembrolizumab was associated with a significantly higher risk of any grade renal events.

This can be described by the increased risk of renal injury in individuals with urothelial carcinoma who are also on pembrolizumab. Additionally, the post-marketing monitoring of Chen et al revealed an increasing incidence of immune-associated kidney side events between 2011 and 2019. Nivolumab monotherapy was connected with a higher percentage of kidney adverse events (33.24%) compared to nivolumab plus ipilimumab combination therapy (23.55%). The lag phase between the commencement of ICIs and AKI is longer than that in other more frequently introduced irAEs. In multicenter research, the median time from the initiation of ICIs to the onset of AKI was reported to be 14 weeks.

A meta-analysis and systematic review, which included 95 studies on about 64 thousand patients, indicated that the simultaneous use of PD-1 and chemotherapy as well as PD-L1 and chemotherapy was related to more severe AKI and more common severe renal complications. In a meta-analysis on 5239 patients with advanced renal cell carcinoma, it was determined that combination therapy with ICIs leads to more proteinuria and renal toxicity than standard treatment with sunitinib. Moreover, recent results of the outcome of cancer patients who received ICIs and developed AKI were associated with a greater risk of mortality. In a cohort study regarding kidney damage caused by ICIs, almost no risk factor and predictor factor for kidney damage was found except for eGFR. Table 1 represents the types of nephrotoxicity and clinical manifestations of ICIs in different types of studies.

Pathophysiology of Immune Checkpoint Inhibitor-related Nephrotoxicity

The exact mechanisms underlying ICI-associated AKI
are still not fully understood. Immune checkpoints are essential in preserving self-tolerance and regular immune responses. B, T, and natural killer T cells, together with stimulated dendritic cells and monocytes, all exhibit increased PD-1 expression after activation.\(^{26}\) PD-L1 is located on the membrane of cancer cells.\(^{27}\) Blocking of anti-tumor immune reactions is the outcome of the PD-1/ PD-L1 interaction.\(^{28}\) As previously mentioned, CTLA-4 is found on the surface of T cells and competes with CD28 to attach CD 80-86 to the dendritic cells.\(^{29}\)

Additionally, in secondary lymphedema, CTLA-4 can control the interactions between T cells and antigen-presenting cells.\(^{30}\) Due to the activation of T cells in cancerous cells caused by the ICI-related inhibition of the PD-1/PD-L1 and CTLA-4 axis, tumor cells could be killed by the release of inflammatory mediators and cytokines. The kickoff of this blockade, however, might cause the liberation of tissue-specific self-reactive T cells that can lower or interrupt immune tolerance against renal antigens. The aberrant activated T cells flow into the kidney, enter the parenchyma, and liberate cytokines that cause an inflammatory response and subsequent renal damage.\(^{3,14,31}\)

In an empirical study, PD-1 knockout animals established persistent systemic inflammation and a renal lesion that resembled lupus glomerulonephritis,\(^{32}\) providing proof that PD-1 suppression or deletion can have negative effects on the kidney. Moreover, exposure to ICIs leads to the generation of circulating antibodies against native antigens or drug-specific antibodies against renal tissue as a result of altering the immune microenvironment.\(^{33}\) This could result in AIN linked to immune complexes. The secondary activation of drug-specific T cells by ICI exposure might plummet the tolerance of these cells to AIN-related drugs. Patients receiving combination therapy of ICIs and PPIs or NSAIDs may be more likely to experience nephrotoxicity as a result of the decreased tolerance. Another proposed mechanism for ICI-related AKI is haptenization.

Tubule cells of the kidney, mesangial cells, or podocytes may identify small-molecular-weight pharmacological molecules such as ICIs or their metabolized constituents as an antigen, resulting in the production of an antigen-antibody complex.\(^{34}\) Moreover, dendritic cells in the parenchyma of the kidney can capture and identify ICIs as a hapten, resulting in tubular destruction and kidney disease.\(^{35}\)

### Immune-related Adverse Effects

Typically, immune checkpoints decrease the expression of T cell responses to protect against probable destructive immune responses, including autoimmune disease. Nevertheless, cancer cells can hijack this pathway to escape the immune system by triggering checkpoints and prohibition of the T cells. Therefore, cancer patients may benefit from treatment when these immune checkpoint pathways are disrupted as this can trigger an anti-tumor immune response. The types of irAEs associated with single-drug treatment that target the CTLA-4 or PD-1 pathways vary, which is in line with the unique roles of immune checkpoints.\(^{36}\) PD-1 and PD-L1 blockers are usually better tolerated than the inhibitors of CTLA-4. A systematic review found that irAEs of grade > 3 are more frequent with CTLA-4 blockers.\(^{37,38}\) It is unclear exactly what biological processes underlie the variations in irAE severity and location with various ICIs. CTLA-4 blockade may result in more T cell growth or less CD4 + CD25 + regulatory T (Treg) cell-related suppression of the immune system, while PD-1 inhibition will likely stimulate fewer T cell clones.\(^{39,40}\) Furthermore, PD-1 can be produced in circulating T cells upon activation during T cell receptor-based signaling even though the majority of them do not express it.\(^{39}\)

In general, the types of irAEs do not appear to be cancer-specific.\(^{37}\) While cross-study evaluations must be interpreted cautiously, certain information indicates that distinct irAE patterns may be driven by distinct organ-specific immune microenvironments in certain cancers as the occurrence of particular irAEs differs amongst different cancer patients receiving identical ICI. Comparing irAEs caused by PD-1 blockers in renal cell carcinoma, non-small-cell lung cancer, and melanoma, for instance, revealed that melanoma cases experienced a lower occurrence of pneumonitis but a higher incidence of gastrointestinal and skin-related irAEs compared with patients with other cancers.\(^{38}\)

As part of their normal function to preserve self-tolerance, Treg cells express CTLA-4 and suppress the

---

**Table 1. The Type of Nephrotoxicity and Clinical Outcome after ICI Administration**

<table>
<thead>
<tr>
<th>Type of Study</th>
<th>Nephrotoxicity Manifestation</th>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Network meta-analysis</td>
<td>Immune-related renal toxicity</td>
<td>ICI administration is associated with an elevated risk of all-grade immune-related renal toxicity</td>
<td>46</td>
</tr>
<tr>
<td>Clinical investigation</td>
<td>AKI</td>
<td>Acute tubulointerstitial nephritis, extrarenal irAE</td>
<td>18</td>
</tr>
<tr>
<td>Systematic review</td>
<td>Renal toxicity</td>
<td>Immune-related renal toxicity</td>
<td>19</td>
</tr>
<tr>
<td>International multicenter cohort study</td>
<td>AKI</td>
<td>Lower baseline valued glomerular filtration rate, the use of proton pump inhibitor, and extrarenal immune-related renal toxicity were each related to a higher risk of AKI</td>
<td>20</td>
</tr>
<tr>
<td>Network meta-analysis</td>
<td>AKI, hypertension, chronic kidney injury</td>
<td>The combination of programmed cell death ligand 1 + ICI was concomitant with an increased rate of kidney events</td>
<td>23</td>
</tr>
<tr>
<td>Meta-analysis</td>
<td>Nephrotoxicity</td>
<td>Increased creatinine and proteinuria compared with sunitinib</td>
<td>21</td>
</tr>
</tbody>
</table>

Note: ICI: Immune checkpoint inhibitor; AKI: Acute kidney injury; irAE: Immune-related adverse event.
Management of Nephrotoxicity

Until proven otherwise, a substantial rise in Cr levels must be taken as a sign of immune-related nephritis during ICI therapy. Due to the degree of toxicity, complication management and starting prompt therapy are strongly advised after the most frequent causes of AKI have been ruled out. As irAEs occur less commonly, no controlled clinical trial has previously been designed to specifically assess the results of therapeutic management and recommendations.40-50 Discontinuation of ICIs and administration of corticosteroids in acute tubulointerstitial nephritis are recommended for first-line therapy.13,31,52 Nevertheless, according to recent research, prednisone in high doses (1 mg/kg at least) should only be used until baseline kidney function restoration or for a maximum of three weeks before a 5- to 6-week tapering period.53 Furthermore, a retrospective study found that the risk of recurrence and recovery of kidney function was comparable for patients with ICI-associated AKI receiving corticosteroids for shorter periods (28 days or less) compared to longer periods.54 Accordingly, the ASCO guidelines recommend using additional immunosuppressive drugs such as infliximab, azathioprine, cyclosporine, cyclophosphamide, or mycophenolate if steroid therapy is ineffective.55

According to retrospective research and case reports, Mycophenolate 1 g twice a day was effective in treating individuals with steroid-refractory irAEs, particularly kidney-related ones.56 The ASCO recommendations state that all patients who experience grade 3 AKI should have their ICIs permanently stopped even though doing so may prevent them from receiving a treatment that could save their lives. Hence, consideration should be given to prior outcomes as well as any available alternative therapies. Rechallenging ICI seems to be a viable and active strategy, but more research is needed to determine whether it is safe to do so after ICI-AKI before considering ICIs once renal injury has been resolved or stopped.

Pharmacokinetics of Immune Checkpoint Inhibitors

Since all ICIs have just recently received approval, there is not much information on the pharmacokinetics/pharmacodynamics relationship between ICIs. The majority of our understanding stems from registration trials conducted in particular patient cohorts. Upon the approval of initial mAbs in cancer therapy, years of clinical experience have been required to comprehend that PK factors may be just as important as somatic biomarkers in predicting clinical consequences.58,59 An understanding of exposure-response associations and the way available biomarkers can predict or anticipate them can help treatment optimization and patient selection for ICIs. Furthermore, characterizing the causes of variation amongst ICIs and evaluating the significance of various substitute endpoints in clinical trials may contribute to the advancement of new drug development.60 ICIs are dispersed and metabolized through a variety of pathways following intravenous administration. Significant attachment to target antigens in plasma and/or tissues lowers the concentration of free ICIs and expands the distribution volume. The main mechanism controlling the transvascular drive of unbound ICIs is convection, the extent of which is restricted by endothelial permeability and organ perfusion. Diffusion and convection show how ICIs are dispersed throughout tissues. By inhibiting the intracellular breakdown of these medications and extending their half-life, the FcRn is in charge of transporting ICIs back into the vascular system. Conversely, clearance increases when antibodies are produced against ICIs. Notwithstanding, the predominant method of ICI clearance persists through proteolytic catabolism, which takes place in peripheral tissues as well as plasma. Finally, an extra clearance pathway is triggered by endocytosis mediated by receptors.61

Conclusion

Despite being a rare side effect of ICI drugs, AKI, failure and delay in diagnosis could result in potentially fatal situations. AKI may develop sometime after the initiation of ICI therapy with a delay of weeks or months, depending on the ICI type. It is advised to stop using ICIs and/or to start using corticosteroids in individuals who have experienced severe toxicity (grade 2). The absence
of sensitive or specific clinical signs to precisely identify ICI-AKI in the absence of a renal biopsy necessitates the creation of non-invasive biomarkers (e.g., blood, urinary, and even imaging-dependent biomarkers) to diagnose cases that can be safely retested following a prescription of ICI-AKI. Moreover, it is important to note that serious electrolyte imbalances can develop during ICI therapy which require frequent monitoring.

Ethics statement
Not applicable.

Disclosure of funding source
The present study was sponsored by the Kidney Research Center, Tabriz University of Medical Sciences (Grant no: 69392), and the ethical approval code for this project is IR.TBZMED.REC.1401.117.

Conflict of interests declaration
None to be declared.

Acknowledgments
We would like to appreciate the cooperation of the Clinical Research Development Unit of Imam Reza General Hospital, Tabriz, Iran in conducting this research.

Data availability statement
This article contains all data produced or analyzed during this study.

Author contributions
Conceptualization: Elham Ahmadian.
Data curation: Fariba Mahmoodpoor.
Formal analysis: Elham Ahmadian.
Investigation: Aygun Nasibova.
Methodology: Mahbube Valiyeva.
Project administration: Fariba Mahmoodpoor.
Resources: Elham Ahmadian.
Software: Aygun Nasibova.
Supervision: Elham ahmadian.
Validation: Elham Ahmadian.
Visualization: Fariba Mahmoodpoor.
Writing-original draft: Fariba Mahmoodpoor, Aygun Nasibova, Mahbube Valiyeva.
Writing-review & editing: Elham Ahmadian.

References
24. Kanbay M, Copur S, Siropold S, Yildiz AB, Berkkan M, Popa


